LAVOIEHEALTHSCIENCE CAMBRIDGE, Mass.–(BUSINESS WIRE)–QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reportstitled Human Amyotrophic Lateral Sclerosis Excitability Phenotype Screen: Target Discovery and Validation by QurAlis founders Kasper Roet, Ph.D., Clifford Woolf, M.D., Ph.D., and Kevin Eggan, Ph.D., who pioneered a high-content, live-cell imaging...